The net amount of deferred gains related to derivative instruments designated as cash flow hedges that is expected to be reclassified from accumulated other comprehensive gains into earnings over the next twelve months is $5,041. The Company's revenue consists of fees for perpetual and term licenses for its software products, post-contract customer support (referred to as maintenance), software as a service ("SaaS"), and professional services including training and other revenue. Revenue is recognized upon ...

Certara Reports First Quarter 2024 Financial Results Reiterates Full Year 2024 Financial Guidance First Quarter Highlights: • Services revenue was $57.3 million, flat compared to $57.3 million in the first quarter of 2023. • Adjusted EBITDA was $29.1 million, compared to $32.3 million in the first quarter of 2023. "We began 2024 with strong financial performance in software, driven by an impressive Net Retention Ratio of 114%, while our services business performed in line with our expectations. As we work t ...

PRINCETON, N.J., April 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates its many scientific software solutions. Customers log into Certara Cloud using a single ID to access and manage their licensed software, linking predictive solutions to modeling and analysis of clinical trial results. "This reusable suite of shared platform services enables us to both integrate ...

PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara also announced ...

Certara Inc. (NASDAQ:CERT) Q4 2023 Earnings Conference Call February 29, 2024 5:00 PM ET Company Participants David Deuchler - IR William Feehery - CEO John Gallagher - CFO Conference Call Participants David Windley - Jefferies Luke Sergott - Barclays Jeff Garro - Stephens Michael Cherny - Leerink Partners Vikram Purohit - Morgan Stanley Max Smock - William Blair Operator Hello and thank you for standing by. Welcome to the Certara Fourth Quarter 2023 Earnings Conference Call. At this time, all participants ...

财务表现 - Certara, Inc. (CERT)在最新季度每股收益为0.09美元，低于Zacks Consensus Estimate的0.11美元[1] - Certara, Inc.在过去四个季度未能超过市场预期的每股收益[2] - Certara, Inc.在2023年12月份的季度营收为8,801万美元，超过了Zacks Consensus Estimate的1.40%[3] 股价走势 - Certara, Inc.股价的未来走势将主要取决于管理层在财报电话会议上的评论[4]

公司财务表现 - Certara, Inc. (NASDAQ:CERT)在2023财年第四季度报告了财务业绩[1] - 第四季度收入为8,800万美元，同比增长2%[2] - 净亏损为1,250万美元，主要是由于Vyasa Analytics的业务表现导致的应收款重估增加[3] - 调整后的EBITDA为2,960万美元，较2022年第四季度的3,190万美元有所下降[10] - 调整后的净收入为14,273万美元，较上一年同期的25,196万美元有所下降[1] - 调整后的每股稀释收益为0.09美元，较上一年同期的0.16美元有所下降[1] 公司收入情况 - 公司在2023年的软件收入为33,619万美元，较上一年同期增长了15%[1] - 公司在2023年的服务收入为54,391万美元，较上一年同期下降了5%[1] - 公司在2023年的总收入为88,010万美元，较上一年同期增长了2%[1] - 公司在2023年的软件收入为131,677万美元，较上一年同期增长了14%[1] - 公司在2023年的服务收入为222,660万美元，较上一年同期增长了1%[1] - 公司在2023年的总收入为354,337万美元，较上一年同期增长了6%[1] 公司成本和费用 - 公司的股权补偿费用为0.05美元，较上一年同期的0.04美元有所增加[2] - 公司的收购相关支出为0.02美元，较上一年同期的0.01美元有所增加[2] - 公司的重组费用为0.01美元[2] - 公司的首年萨班斯-奥克斯利成本为0.01美元[2] - 公司的调整后稀释每股收益为0.43美元，较上一年同期的0.46美元有所下降[2]

Table of Contents __________________________________ __________________________________ __________________________________ __________________________________ Title of each class Trading SymbolName of each exchange on which registered Common stock, par value $0.01 per share CERT The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended ...

1. As of 12/31/2022 Differentiated scientific and technology expertise Software Tech-driven Services © Copyright 2023 Certara, L.P. All rights reserved. PopPK Dose-response Renal impairment Hepatic impairment 5 6 Renal impairment Hepatic impairment Pediatric HIV Animal QT interval prolongation 3 PopPK Dose-response <2000 2000 - 2010 2011 - 2015 2016 - 2020 1. Science Direct search for publications by key search terms 2. Model‐Informed Drug Development: Current US Regulatory Practice and Future Consideration ...

财务数据和关键指标变化 - 第三季度总收入为8560万美元,同比增长1% [32] - 软件收入为3130万美元,同比增长10% [32] - 服务收入为5420万美元,同比下降4% [35] - 软件预订额为2720万美元,同比增长7% [34] - 服务预订额为5760万美元,同比增长6% [36] - 调整后EBITDA为2880万美元,同比下降12% [40] - 调整后每股收益为0.11美元,同比增长10% [41] 各条业务线数据和关键指标变化 - 生物模拟软件和Pinnacle 21业务保持强劲增长 [32][33] - 监管服务业务实现顺序改善,同比增长 [26] - 生物模拟服务业务表现符合预期,客户需求稳步改善 [27] 各个市场数据和关键指标变化 - 大型制药客户(Tier 1)的预订额受行业和宏观经济影响有所下降 [13] - 中小型生物科技公司(Tier 3)的预订额实现增长 [24] 公司战略和发展方向及行业竞争 - 公司持续投资人工智能等新技术,推出Certara AI和Co-Author等新产品 [18][19][20][21][22] - 公司看好生物模拟业务的长期增长前景,将继续投资并推动其在客户中的广泛应用 [29][47] - 公司正在整合服务业务,以提高协调性和执行力 [25][26][27][28] 管理层对经营环境和未来前景的评论 - 公司看到客户支出环境有所稳定,但仍存在一些短期不确定性 [9][24] - 公司对未来增长保持信心,将继续专注于一致的执行 [29][30][46][47] - 公司认为人工智能等新技术将为产品带来重大机遇 [18][19][20][21][22][23] 问答环节重要的提问和回答 问题1 **Jeff Garro 提问** 询问软件业务的续约率和SaaS/许可证收入占比 [52][53] **John Gallagher 回答** 续约率受到一些时间性因素影响,但预计第四季度将恢复正常水平 [53][54] 问题2 **David Windley 提问** 询问服务业务的人员利用率和未来招聘计划 [63][64][65] **John Gallagher 回答** 人员利用率符合预期,公司正在适当控制非交付人员的招聘 [64][65] 问题3 **Mike Ryskin 提问** 询问公司对业务环境稳定性的判断依据 [72][73][74][75][76][77][78][79][80][81] **William Feehery 和 John Gallagher 回答** 公司看到执行力提升和管线情况改善,对未来保持信心,但仍面临一些行业动荡 [73][74][75][79][80][81]